Oppenheimer & Co. Inc. Increases Stake in RxSight, Inc. (NASDAQ:RXST)

Oppenheimer & Co. Inc. grew its position in RxSight, Inc. (NASDAQ:RXST) by 15.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,099 shares of the company’s stock after acquiring an additional 823 shares during the period. Oppenheimer & Co. Inc.’s holdings in RxSight were worth $301,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Amalgamated Bank increased its position in RxSight by 21.3% during the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after buying an additional 207 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of RxSight by 0.7% during the third quarter. Principal Financial Group Inc. now owns 36,046 shares of the company’s stock valued at $1,782,000 after acquiring an additional 240 shares during the last quarter. Crossmark Global Holdings Inc. boosted its stake in shares of RxSight by 3.2% during the second quarter. Crossmark Global Holdings Inc. now owns 7,861 shares of the company’s stock valued at $473,000 after acquiring an additional 242 shares during the last quarter. RiverPark Advisors LLC increased its position in RxSight by 9.6% during the 2nd quarter. RiverPark Advisors LLC now owns 3,379 shares of the company’s stock worth $203,000 after purchasing an additional 297 shares in the last quarter. Finally, CWM LLC raised its stake in RxSight by 727.5% in the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after purchasing an additional 371 shares during the last quarter. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Jesse Anderson Corley acquired 11,111 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The stock was acquired at an average cost of $45.37 per share, for a total transaction of $504,106.07. Following the completion of the acquisition, the director now directly owns 468,571 shares of the company’s stock, valued at approximately $21,259,066.27. The trade was a 2.43 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Ilya Goldshleger sold 4,875 shares of RxSight stock in a transaction on Friday, November 15th. The shares were sold at an average price of $46.00, for a total value of $224,250.00. Following the transaction, the insider now owns 42,246 shares in the company, valued at approximately $1,943,316. This trade represents a 10.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 52,720 shares of company stock valued at $2,603,950. Insiders own 9.36% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on RXST shares. Oppenheimer decreased their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 6th. Wells Fargo & Company decreased their price objective on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Jefferies Financial Group started coverage on RxSight in a research report on Tuesday, October 29th. They set a “buy” rating and a $72.00 target price on the stock. Finally, Stifel Nicolaus decreased their price target on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, RxSight currently has an average rating of “Buy” and a consensus price target of $61.63.

RxSight Stock Down 0.5 %

Shares of RXST stock opened at $44.83 on Friday. The company has a market cap of $1.81 billion, a P/E ratio of -54.01 and a beta of 1.19. The business has a 50 day moving average of $49.39 and a two-hundred day moving average of $52.80. RxSight, Inc. has a 52 week low of $28.54 and a 52 week high of $66.54.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.